NEPHROSCAN Trademark

Trademark Overview

On Wednesday, September 9, 2020, a trademark application was filed for NEPHROSCAN with the United States Patent and Trademark Office. The USPTO has given the NEPHROSCAN trademark a serial number of 90169569. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Wednesday, June 14, 2023. This trademark is owned by Theragnostics Limited. The NEPHROSCAN trademark is filed in the Pharmaceutical Products category with the following description:

radiopharmaceuticals, namely, kidney imaging agents for medical diagnosis, monitoring and assessment
nephroscan

General Information

Serial Number90169569
Word MarkNEPHROSCAN
Filing DateWednesday, September 9, 2020
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateWednesday, June 14, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicesradiopharmaceuticals, namely, kidney imaging agents for medical diagnosis, monitoring and assessment
Pseudo MarkNEPHRO SCAN

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, July 24, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTheragnostics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLondon W1W7PA

Trademark Events

Event DateEvent Description
Monday, September 25, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Monday, September 25, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Wednesday, June 14, 2023ABANDONMENT - AFTER EX PARTE APPEAL
Wednesday, June 14, 2023EXPARTE APPEAL TERMINATED
Friday, March 31, 2023EX PARTE APPEAL-REFUSAL AFFIRMED
Tuesday, November 15, 2022REPLY BRIEF FILED - CHECK TTAB FILES
Monday, October 24, 2022NOTIFICATION OF EXAMINERS STATEMENT E-MAILED
Monday, October 24, 2022EXAMINERS STATEMENT E-MAILED
Monday, October 24, 2022EXAMINERS STATEMENT - COMPLETED
Tuesday, August 23, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, May 18, 2022NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, May 18, 2022ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, May 18, 2022ACTION CONTINUING FINAL - COMPLETED
Thursday, March 3, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 3, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 2, 2022ASSIGNED TO LIE
Monday, February 28, 2022ASSIGNED TO LIE
Friday, February 25, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, February 25, 2022EX PARTE APPEAL-INSTITUTED
Friday, February 25, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, February 25, 2022EXPARTE APPEAL RECEIVED AT TTAB
Wednesday, August 25, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, August 25, 2021FINAL REFUSAL E-MAILED
Wednesday, August 25, 2021FINAL REFUSAL WRITTEN
Saturday, July 24, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 23, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 23, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 27, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 27, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 27, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 29, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 29, 2021NON-FINAL ACTION E-MAILED
Friday, January 29, 2021NON-FINAL ACTION WRITTEN
Monday, January 18, 2021ASSIGNED TO EXAMINER
Friday, January 15, 2021ASSIGNED TO EXAMINER
Thursday, October 15, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

nephroscan diagnosis monitoring assessment medical agents namely kidney imaging radiopharmaceuticals